Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

17.20 USD +0.20 (+1.15%)
Streaming Delayed Price Updated: 2:20 PM EDT, Sep 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,816
Open 17.14
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 17.00
Today's Range 17.10 - 17.22
52wk Range 13.41 - 18.46
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on... 
From PR Newswire
Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical... 
From PR Newswire

Performance

YTD
+11.29%
+11.29%
1 Month
+7.87%
+7.87%
3 Month
-2.74%
-2.74%
6 Month
+3.15%
+3.15%
1 Year
+12.83%
+12.83%

More News

Read More
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
From PR Newswire
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
From PR Newswire
U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
From PR Newswire
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
From PR Newswire
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
From PR Newswire
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Tags Benzinga General ALPMF
From Benzinga
New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress
From PR Newswire
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Tags gene therapy Biotech ALPMY
From Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Tags Long Ideas News Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.